Clinical Trial Update: Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase I/Randomized, Double-Blind Phase II study evaluating AZD5363 in combination with DP chemotherapy for metastatic castration-resistant prostate c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AZD5363 (capivasertib)

Snippet

Sponsor: University Hospital Southampton NHS Foundation Trust | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED